Key Takeaways
- Alis Biosciences launched with a new fund to help publicly traded biotech companies maximize the return of cash to investors when strategic alternatives are limited.
- The London-based firm’s strategy aligns with an emerging trend of individual investors asking companies in the middle of evaluating their options to wind down and return cash to shareholders.
- Alis will benefit from the upside when remaining intellectual property is sold or developed. The firm will go public to execute at least one of the structures it will facilitate for winding down companies.
At a time when accessing capital has become increasingly difficult, leaving more and more biopharma firms to consider a range of less-than-stellar strategic alternatives, Alis Biosciences has emerged with a new fund designed to help public companies
London-based Alis announced its strategy on 18 April, but did not disclose how much money it has raised to help biopharma companies liquidate their assets to the benefit of their shareholders
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
